Firendia 10 mg (Tablet)
Unit Price: ৳ 80.00 (3 x 10: ৳ 2,400.00)
Strip Price: ৳ 800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Reduces risk of sustained eGFR decline
- Reduces risk of end-stage kidney disease
- Reduces risk of cardiovascular death
- Reduces risk of nonfatal myocardial infarction
- Reduces risk of hospitalization for heart failure
- Indicated for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Pharmacology
- Nonsteroidal selective antagonist of the mineralocorticoid receptor (MR)
- Blocks MR mediated sodium reabsorption
- Potent and selective for the MR
- No relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors
- Mean systolic blood pressure decrease of 3 mmHg
- Mean diastolic blood pressure decrease of 1-2 mmHg
- Complete absorption after oral administration
- Metabolized by CYP3A4
- Secreted in urine
Dosage & Administration
- Recommended starting dosage of 10 mg or 20 mg orally once daily
- Increase dosage after 4 weeks to the target dose of 20 mg once daily
- Recommended dosage based on eGFR thresholds
- May be taken with or without food
- Tablets can be crushed and mixed with water or soft foods for patients unable to swallow whole tablets
- Monitoring of serum potassium levels
- Missed dose instructions
Interaction
- Contraindicated with strong CYP3A4 inhibitors
- Avoid concomitant intake of grapefruit or grapefruit juice
- Monitor serum potassium during concomitant use with moderate or weak CYP3A4 inhibitors
- Avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- Contraindicated in concomitant use with strong CYP3A4 inhibitors
- Contraindicated in patients with adrenal insufficiency
Side Effects
- Adverse reactions include hyperkalemia, hypotension, and hyponatremia
Pregnancy & Lactation
- No available data on use in pregnancy
- Animal studies show developmental toxicity
- No data on presence in human milk
- Avoid breastfeeding during treatment and for 1 day after treatment
Precautions & Warnings
- Can cause hyperkalemia
- Risk increases with decreasing kidney function
- Do not initiate if serum potassium is > 5.0 mEq/L
- Monitor serum potassium and eGFR
- More frequent monitoring for patients at risk for hyperkalemia
Use in Special Populations
- Safety and efficacy not established in patients below 18 years
- No overall differences in safety or efficacy observed in geriatric patients
- No dose adjustment required in geriatric patients
- Avoid use in severe hepatic impairment
- Consider additional serum potassium monitoring in patients with moderate hepatic impairment
Overdose Effects
- Interrupt treatment in case of suspected overdose
- Most likely manifestation is hyperkalemia
- Standard treatment for hyperkalemia should be initiated
- Unlikely to be efficiently removed by hemodialysis
Therapeutic Class
- Mineralocorticoid Receptor Antagonists
Storage Conditions
- Keep below 30°C temperature
- Keep away from light and moisture
- Keep out of the reach of children